Product Name | Rapamycin |
Description |
mTOR inhibitor |
Purity | >98% |
CAS No. | 53123-88-9 |
Molecular Formula | C51H79NO13 |
Molecular Weight | 914.18 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble to 100 mM in ethanol, and to 50 mM in DMSO |
Source | Synthetic |
Appearance | White Solid |
SMILES | C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC |
InChI | InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63- |
InChIKey | QFJCIRLUMZQUOT-HPLJOQBZSA-N |
Safety Phrases |
Classification: Harmful. May be harmful if inhaled, swallowed or absorbed through skin. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection Risk Phrases: R68- Possible risk of irreversible effect |
Cite This Product | Rapamycin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-212) |
Alternative Names | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-2-propanyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatr icyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene2,3,10,14,20-pentone |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, mTOR Inhibitors |
PubChem ID | 5284616 |
Scientific Background | Rapamycin or Sirolimus is an immunosuppressant and antifungal. It inhibits the response to interleukin-2, and therefore blocks activation of T and B cells. It binds FKBP12 which then inhibits the mTOR pathway (1). There is also potential treatment for Alzheimer;s, autism and HIV infection (2-3). |
References |
1. Gruppuso P.A., Boylan J.M., and Sanders J.A. (2011) Cell Cycle. 10(7): EPub. 2. Ehninger D., et al. (2008) Nat. Med. 14(8): 843-848. 3. Donia M., McCubrey J.A., Bendtzen K., and Nicoletti F. (2010) Br J Clin Pharmacol. 70(6): 784-793. |
Reviews
There are no reviews yet.